Executive change at Harrow sets new focus on accounting leadership
Harrow (HROW) disclosed that Chief Accounting Officer and principal accounting officer Randall E. Pollard left his roles on 4 September 2026, with President and CFO Andrew R. Boll now also serving as principal accounting officer.
The board assigned Boll the additional responsibilities without extra compensation. The change concentrates financial oversight within Harrow’s senior leadership and may prompt investors to reassess how the company manages reporting and controls.
Harrow’s share price closed at US$38.54 on 4 September, with short term momentum mixed as the 7 day share price return of 3.41% contrasts with a weaker 30 day share price return that is down 4.70%.
Over a longer horizon, investors have seen a 4.19% total shareholder return over the past year and a 3 year total shareholder return of 159.70%. This helps put this executive reshuffle into the context of a stock that has already delivered significant gains for long term holders.
Spot similar momentum and leadership stories by scanning our curated 19 high quality undiscovered gems alongside Harrow.
Harrow trades at a steep discount to both analyst targets and one intrinsic value estimate after this executive reshuffle. Is the market rightly cautious about the risks, or overstating concerns around this growing eyecare platform?
Most Popular Narrative: 43.6% Undervalued
Harrow’s most followed valuation narrative places fair value at $68.38, well above the last close at $38.54, which frames this accounting leadership change against a stock already seen as discounted.
The rapidly growing demand for Harrow’s portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool, supporting sustainable long-term revenue growth.
Read the complete narrative.Read the complete narrative.
Want to see what sits behind that fair value gap? The narrative leans on brisk revenue expansion, sharply higher margins, and a future earnings profile that supports a richer multiple. The full breakdown shows how those ingredients combine into that $68.38 figure.
Result: Fair Value of $68.38 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this Harrow narrative can be tested quickly if pricing pressure on key drugs or slower uptake for products like VEVYE and IHEEZO reduces revenue.
Next Steps
The narrative around Harrow may sound upbeat, yet the real test is how the numbers stack up for you. Review the company’s 3 key rewards.
Looking for more investment ideas beyond Harrow?
If Harrow has your attention, do not stop here. Fresh ideas across the market can help you stress test your thinking and sharpen your next move.
- Target dependable cash generators by reviewing companies on our 11 dividend fortresses that focus on income as well as resilience.
- Hunt for potential mispricings by scanning the 47 high quality undervalued stocks and see which stocks currently trade below assessed value with solid fundamentals.
- Protect the downside first by checking companies in our 81 resilient stocks with low risk scores that pair financial strength with more measured risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Harrow might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
You can copy Bill Ackman and buy Netflix. Knowing why you did is the hard part.
Netflix case is interesting. The scariest competitor is the one that does not need to make money. Amazon can run video at a loss forever because it is really a Prime retention tool with a content budget attached. On the other hand there is Youtube.
Pershing Square hasn’t beaten the S&P over the last five years, though the long-run record is genuinely good. I like Ackman as a person. I enjoy listening to Ackman and that’s about where it ends for me.
Mitchell Lawler
Market Insights
What 13F filings won’t tell you about a billionaire’s stock picks
Fresh 13F filings are where some investors go to find their next stock pick. The problem is it’s missing some of the most important details for making a good investment.
30
Sep 4, 2026
About NasdaqGM:HROW
Harrow
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Undervalued with high growth potential.
Similar Companies
Market Insights
What 13F filings won’t tell you about a billionaire’s stock picksMI
Mitchell Lawler
Great earnings season, but are the earnings real?AN
Andrew Legget
Which payment stocks actually get paid?MI
Mitchell Lawler
Advertisement
Weekly Picks
Lou_Baseneseon Oncolytics Biotech·19 days ago
The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech
Fair Value:US$3.575.9% undervalued
67followersusers have followed this narrative
·1commentusers have commented on this narrative
·17likesusers have liked this narrative
AN
andrei9868on ServiceNow·22 days ago
The Platform Turning Enterprise Chaos into Autonomous Workflows
John_Ericon Vistra·6 days ago
Vistra Fell 38%. Adjusted EBITDA Rose 31%. Here’s the $472 Million Reason They Disagree.
HarishPKon EverQuote·16 days ago
EverQuote and an Asymmetric Investment Opportunity
RecentlyUpdated Narratives
RockeTelleron Meeka Metals·about 3 hours ago
Meeka Metals: 1.2 Moz High-Grade Gold Producer – Open Pit Failure to Underground Transition?
RogueEPon Quanex Building Products·about 5 hours ago
The Market Is Pricing a Housing Cyclical. We See a Self-Funding Consolidator
Fair Value:US$33.3331.2% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
JO
John_Ericon Hamilton Lane·about 6 hours ago
Analysts Cut Their Targets. The Co-Chairman Cut a Check.
Popular Narratives
oscargarciaon NVIDIA·3 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
John_Ericon MercadoLibre·1 day ago
MercadoLibre and the Spreadsheet Trick That Decides Everything
Fair Value:US$3.68k46.2% undervalued
129followersusers have followed this narrative
·3commentsusers have commented on this narrative
·18likesusers have liked this narrative
ANAnalystConsensusTargeton NVIDIA·about 1 month ago
